GlassScriptPhysician profile
Edward J Miller
NPI 1891763355
$7,624.35
in general payments reported to CMS, 2019-2025
40 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $282 · 2021: $741 · 2022: $671 · 2023: $1,209 · 2024: $1,453 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,243.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,117.31 | 2019-2020 | |
| Novo Nordisk INC | $992.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $945.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $910.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $671.07 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $488.30 | 2022-2025 | |
| Pfizer INC. | $368.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.89 | 2021-2024 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $185.44 | 2020-2024 | Veozah |
| Amarin Pharma, INC. | $184.39 | 2019-2023 | |
| Glaxosmithkline, LLC. | $163.59 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $137.08 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.63 | 2021-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $103.39 | 2019-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $100.21 | 2019-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.